2.31 USD
▼-0.08-3.35%
盘后 2.31 -0.22%
2026-09-15
市值
$420.59M
市盈率
—
EPS
-0.43
股息率
—
52 周区间
1.33 – 2.61
成交量
480.80K
Beta
0.96
目标价
6.00
52W 低 1.3352W 高 2.61
价格走势
公司简介
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role...